Olympiad Research’s Health Catalyst HCAT Stock Holding History

Olympiad Research’s Portfolio HCAT Stock Details HCAT Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2024 Q3	–	Sell	-18,987	Closed	-$121K	–	397
2024 Q2	$121K	Sell	18,987 -16,660	-47%	-$107K	0.09%	328
2024 Q1	$268K	Buy	35,647 +10,858	+44%	+$99.1K	0.18%	228
2023 Q4	$230K	Buy	+24,789	New	+$203K	0.18%	243

Other funds holding HCAT

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

FLAM

First Light Asset Management Edina, Minnesota $1.65B AUM 203.21% 1-Year Est. Return

Impax Asset Management Group London, United Kingdom $15.4B AUM 26.43% 1-Year Est. Return

Daventry Group New York $133M AUM 32.28% 1-Year Est. Return

Primecap Management Pasadena, California $169B AUM 114.72% 1-Year Est. Return

Bank of New York Mellon New York $609B AUM 40.19% 1-Year Est. Return

Nepsis Inc Minneapolis, Minnesota $317M AUM 37.22% 1-Year Est. Return

Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return

Millennium Management New York $276B AUM 44.8% 1-Year Est. Return

Olympiad Research's HCAT Position: Q3 2024 in Review

Olympiad Research sold out of Health Catalyst (HCAT) in Q3 2024, closing a stake of 18,987 shares — an estimated $121K sold.

Olympiad Research first reported a position in HCAT in Q4 2023 and held it in 3 quarters. The position peaked at $268K in Q1 2024. 159 funds tracked by Wall St. Rank hold HCAT as of Q3 2024.

Olympiad Research reported no remaining Health Catalyst position as of Q3 2024 after selling out during the quarter.
Olympiad Research sold 18,987 Health Catalyst shares in Q3 2024, an estimated $121K.
Olympiad Research first reported a position in Health Catalyst in Q4 2023 and held it in 3 quarters.
Olympiad Research's Health Catalyst position peaked at $268K in Q1 2024.
159 funds tracked by Wall St. Rank held Health Catalyst as of Q3 2024.

Based on Olympiad Research's 13F filing for Q3 2024, filed 31 Oct 2024.